Childbirth is a roll of the dice. A genetic gamble. And the stakes couldn’t be higher—life, or at least its quality. In India, chromosomal abnormalities—which can result in conditions ranging from Down to Patau syndrome—occur in 1 in every 166 children conceived. The rate of Down Syndrome, 1 in 800. Odds no parent is comfortable with. Nor should they be. India is home to the largest number of children born with genetic disorders in the world.
Faced with such a predicament, prospective parents are an anxious lot.
Gen(i)e in a bottle
NIPT is expensive, but India can’t afford to miss out
Can the new prenatal genetic test capture the world’s largest market—India’s 25 million birth cohort? Only if it gets cheaper. Much cheaper
MedGenome, the first to market the non-invasive prenatal test (NIPT) in India, is trying to corner the NIPT market
While the NIPT market is still in its nascency, MedGenome estimates it can become a Rs 400 crore industry
MedGenome has started offering NIPT at lower prices to healthcare providers in its network to drive adoption
Will the expensive diagnostic test become a standard in a cost-sensitive market such as India?